The Claim
In children with Graves' disease, TRAb levels below 10 IU/L at diagnosis are associated with a higher likelihood of achieving sustained remission after antithyroid drug therapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Children with Graves' disease who have TRAb levels below 10 IU/L when first diagnosed are more likely to achieve sustained remission after treatment with antithyroid drugs.
See the scientific wording
In children with Graves' disease, TRAb levels below 10 IU/L at diagnosis are associated with a higher likelihood of achieving sustained remission after antithyroid drug therapy, suggesting that lower autoantibody levels may indicate a more favorable disease course.
When children have fewer antibodies targeting their thyroid gland at diagnosis, their immune system is less actively attacking it, allowing the body to stop the attack permanently after treatment ends.
What the research says
1 studyStudy: The role of the FT3/FT4 ratio in predicting remission and relapse in pediatric Graves’ disease
Kids with Graves' disease who have lower levels of a specific antibody (TRAb) when first diagnosed are more likely to stay healthy after stopping their medicine, and this study found that to be true.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.